Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predominance of 23S rRNA mutants among non-erm, non-mef macrolide-resistant clinical isolates of Streptococcus pneumoniae collected in the United States in 1999-2000.

Antimicrobial agents and chemotherapy - 1 Jul 2005

Davies Todd A, Bush Karen, Sahm Daniel, Evangelista Alan

Abstract excerpt

A total of 322 erythromycin-resistant pneumococci from TRUST 3 and TRUST 4 United States surveillance studies (1999-2000) were screened for 23S rRNA, L4, and L22 gene mutations. Nineteen isolates, two with mefA, had mutations at position 2058 or 2059 in 23S rRNA. Two had a 69GTG71-to-TPS substitution in L4; one of these also contained ermA.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Bacterial
Share to Erythromycin
Share to Macrolides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Microbial Sensitivity Tests

Share to Population Surveillance

Share to RNA, Ribosomal, 23S

Share to Streptococcus pneumoniae

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 15980393
DOI: 10.1128/AAC.49.7.3031-3033.2005
PMCID: PMC1168632

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predominance of 23S rRNA mutants among non-erm, non-mef macrolide-resistant clinical isolates of Streptococcus pneumoniae collected in the United States in 1999-2000.PMID 15980393Read ↗

Epidemiology of macrolide and/or lincosamide resistant Streptococcus pneumoniae clinical isolates with ribosomal mutations.Semantic proximity Read ↗

Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3.Semantic proximity Read ↗

Mutations within the rplD Gene of Linezolid-Nonsusceptible Streptococcus pneumoniae Strains Isolated in the United States.Semantic proximity Read ↗

Increase in pneumococcus macrolide resistance, United States.Semantic proximity Read ↗

Differences in the frequency of 23S rRNA gene mutations in Mycoplasma pneumoniae between children and adults with community-acquired pneumonia: clinical impact of mutations conferring macrolide resistance.Semantic proximity Read ↗

Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.Semantic proximity Read ↗

The Prevalence of 23S rRNA Mutations in ML-Resistant M. pneumoniae Isolates to Clarithromycin in Patients with Respiratory InfectionsSemantic proximity Read ↗

Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003.Semantic proximity Read ↗

In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.Semantic proximity Read ↗

Macrolide-resistance mechanisms in Streptococcus pneumoniae isolates from Belgium.Semantic proximity Read ↗

Ribosomal mutations in Streptococcus pneumoniae clinical isolates.Semantic proximity Read ↗

Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.